13 Best Forever Stocks to Buy Right Now

Page 8 of 12

5. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81

Johnson & Johnson (NYSE:JNJ) is a leading player in the healthcare sector, including sub-sectors such as medicines, Medtech equipment, and consumer health goods. The company is renowned for creating medications to treat a variety of ailments and diseases, including cancer, diabetes, and HIV/AIDS. Johnson & Johnson (NYSE:JNJ) also has several other potential development prospects, including the robotic-assisted surgical business.

On February 3, Guggenheim increased its price target for Johnson & Johnson (NYSE:JNJ) from $162 to $166 while reaffirming its Neutral rating on the company’s shares. The adjustment followed JNJ’s Q4 2024 results, which showed $22.5 billion in revenue and $2.04 in profits per share. Guggenheim praised Johnson & Johnson’s performance, including the initial forecast for 2025, despite increased competition from Stelara biosimilars in the US market. The recent acquisition of ITCI is also intended to increase Johnson & Johnson’s foothold in the mental health industry, with the transaction slated to be completed in the second quarter of 2025.

On January 13, Johnson & Johnson (NYSE:JNJ) announced the $14.6 billion acquisition of IntraCellular, a neurological pharmaceutical. This acquisition will provide JNJ with access to Caplyta, an oral medication used to treat bipolar disorder and schizophrenia.

Page 8 of 12